24/7 Market News Snapshot 10 June, 2025 – MacroGenics, Inc. (NASDAQ:MGNX)
DENVER, Colo., 10 June, 2025 (www.247marketnews.com) – (NASDAQ:MGNX) are discussed in this article.
MacroGenics, Inc. is experiencing a notable pre-market surge, with shares currently trading at $2.307, reflecting a significant increase of 40.67% from the previous close of $1.640. This surge is accompanied by a heightened trading volume of 3.61 million shares, indicating strong investor interest and confidence in the company’s potential for growth. Such momentum positions MacroGenics as a stock to watch closely as developments unfold throughout the day.
In a major development, the biopharmaceutical company has successfully secured a substantial $70 million upfront cash investment through a strategic royalty purchase agreement with Sagard Healthcare Partners. This significant financial boost enhances MacroGenics’ stability and extends its cash runway into the first half of 2027.
The agreement entails a capped royalty interest on future global net sales of ZYNYZ (retifanlimab-dlwr), a novel PD-1 inhibitor that was initially developed by MacroGenics and has been advanced through its collaboration with Incyte. Importantly, despite this partnership, MacroGenics retains additional economic interests associated with ZYNYZ, including potential future milestone payments and an ongoing role in global commercial manufacturing efforts.
The inflow of $70 million, combined with existing resources, anticipated future payments from partners, and cost-optimization strategies, positions MacroGenics for continued investment in its clinical and preclinical programs. As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $154.1 million.
ZYNYZ is recognized as a promising advancement in cancer therapy, recently approved for the treatment of adult patients with specific types of squamous cell carcinoma and Merkel cell carcinoma. The ongoing commercial success of ZYNYZ will depend on further validation of its clinical benefits in forthcoming confirmatory trials. Through this collaboration with Sagard, MacroGenics reaffirms its dedication to driving innovation in cancer treatment to enhance patient outcomes.